Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment

Julie Refardt, Anissa Pelouto, Laura Potasso, Ewout J Hoorn, Mirjam Christ-Crain, Julie Refardt, Anissa Pelouto, Laura Potasso, Ewout J Hoorn, Mirjam Christ-Crain

Abstract

Background: Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. In contrast to acute hyponatremia where the need for immediate treatment is well-recognized, chronic hyponatremia is often considered not clinically relevant. This is illustrated by reports showing that appropriate laboratory tests are ordered in <50% of patients and that up to 75% are still hyponatremic at discharge. At the same time, emerging evidence suggests an association between hyponatremia and adverse events including increased risk of mortality and rehospitalization. Methods: This is a randomized (1:1 ratio) controlled, superiority, parallel-group international multi-center trial with blinded outcome assessment. In total 2,278 participants will be enrolled. Participants will be randomly assigned to undergo either targeted correction of plasma sodium levels or standard of care during hospitalization. The primary outcome is the combined risk of death or re-hospitalization within 30 days. Discussion: All data on hyponatremia and mortality are derived from observational studies and often lack methodologic robustness. Consequently, the direct impact of hyponatremia on mortality and rehospitalization risk is still debated, resulting in a clinical equipoise whether in-hospital chronic hyponatremia should be treated or not. Therefore, a randomized controlled trial is required to study whether targeted plasma sodium correction reduces the risk of mortality and rehospitalization associated with hyponatremia. Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03557957.

Keywords: SIAD(H); diuretics [MeSH]; hyponatremia; mortality; outcome; sodium; trial; urea.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Refardt, Pelouto, Potasso, Hoorn and Christ-Crain.

Figures

Figure 1
Figure 1
Study design flowchart.

References

    1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. (2006) 119:S30–S5. 10.1016/j.amjmed.2006.05.005
    1. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. . Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dialysis Transplantation. (2014) 29(suppl_2):i1–39. 10.1093/ndt/gfu040
    1. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. . Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. (2013) 126:S1–S42. 10.1016/j.amjmed.2013.07.006
    1. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med. (2006) 119:S79–82.
    1. Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo Iii JA, Chiong JR, et al. . Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. (2015) 88:167–77.
    1. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. (2006) 119:71.e1–8. 10.1016/j.amjmed.2005.09.026
    1. Upala S, Sanguankeo A. Association between hyponatremia, osteoporosis, and fracture: a systematic review and meta-analysis. J Clin Endocrinol Metabol. (2016) 101:1880–6. 10.1210/jc.2015-4228
    1. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. . Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Int Med. (2007) 167:1998–2005. 10.1001/archinte.167.18.1998
    1. Rusinaru D, Buiciuc O, Leborgne L, Slama M, Massy Z, Tribouilloy C. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol. (2009) 103:405–10. 10.1016/j.amjcard.2008.09.091
    1. Lu DY, Cheng HM, Cheng YL, Hsu PF, Huang WM, Guo CY, et al. . Hyponatremia and worsening sodium levels are associated with long-term outcome in patients hospitalized for acute heart failure. J Am Heart Assoc. (2016) 5:e002668.
    1. Goldberg A, Hammerman H, Petcherski S, Nassar M, Zdorovyak A, Yalonetsky S, et al. . Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Int Med. (2006) 166:781–6. 10.1001/archinte.166.7.781
    1. Burkhardt K, Kirchberger I, Heier M, Zirngibl A, Kling E, von Scheidt W, et al. . Hyponatraemia on admission to hospital is associated with increased long-term risk of mortality in survivors of myocardial infarction. Eur J Preventive Cardiol. (2015) 22:1419–26. 10.1177/2047487314557963
    1. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. . Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. (2004) 40:802–10. 10.1002/hep.1840400409
    1. Nair V, Niederman MS, Masani N, Fishbane S. Hyponatremia in community-acquired pneumonia. Am J Nephrol. (2007) 27:184–90. 10.1159/000100866
    1. Scherz N, Labarère J, Méan M, Ibrahim SA, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respiratory Critical Care Med. (2010) 182:1178–83. 10.1164/rccm.201003-0481OC
    1. Waikar SS, Curhan GC, Brunelli SM. Mortality associated with low serum sodium concentration in maintenance hemodialysis. Am J Med. (2011) 124:77–84. 10.1016/j.amjmed.2010.07.029
    1. Funk G-C, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, et al. . Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. (2010) 36:304–11.
    1. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. (2009) 122:857–65. 10.1016/j.amjmed.2009.01.027
    1. Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. (2005) 25:240–9. 10.1159/000086019
    1. Holland-Bill L, Christiansen CF, Heide-Jørgensen U, Ulrichsen SP, Ring T, Jørgensen JO, et al. . Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients. Eur J Endocrinol. (2015) 173:71–81. 10.1530/EJE-15-0111
    1. Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond associations. Am J Kidney Dis. (2013) 62:139–49. 10.1053/j.ajkd.2012.09.019
    1. Refardt J, Kling B, Krausert K, Fassnacht M, von Felten S, Christ-Crain M, et al. . Impact of chronic hyponatremia on neurocognitive and neuromuscular function. Eur J Clin Invest. (2018) 48:e13022. 10.1111/eci.13022
    1. Ahluwalia V, Heuman DM, Feldman G, Wade JB, Thacker LR, Gavis E, et al. . Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. J Hepatol. (2015) 62:75–82. 10.1016/j.jhep.2014.07.033
    1. Jamookeeah C, Robinson P, O'Reilly K, Lundberg J, Gisby M, Ländin M, et al. . Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocrine Disord. (2016) 16:1–9. 10.1186/s12902-016-0104-z
    1. Donzé JD, Beeler PE, Bates DW. Impact of hyponatremia correction on the risk for 30-day readmission and death in patients with congestive heart failure. Am J Med. (2016) 129:836–42. 10.1016/j.amjmed.2016.02.036
    1. Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, Peri A. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS ONE. (2015) 10:e0124105. 10.1371/journal.pone.0124105
    1. De Vecchis R, Di Maio M, Di Biase G, Ariano C. Effects of hyponatremia normalization on the short-term mortality and Rehospitalizations in patients with recent acute decompensated heart failure: a retrospective study. J Clin Med. (2016) 5:92. 10.3390/jcm5100092
    1. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. . Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. (2006) 355:2099–112. 10.1056/NEJMoa065181
    1. Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, et al. . Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. J Clin Pharmacol. (2014) 54:1362–7. 10.1002/jcph.342
    1. Li L, Bai H, Zhu WL. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Zhonghua xin xue guan bing za zhi. (2011) 39:936–40.
    1. Salahudeen AK, Ali N, George M, Lahoti A, Palla S. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer. (2014) 120:744–51. 10.1002/cncr.28468
    1. Bhandari S, Peri A, Cranston I, McCool R, Shaw A, Glanville J, et al. . A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clinical endocrinology. (2017) 86:761–71. 10.1111/cen.13315
    1. Woodfine JD, Sood MM, MacMillan TE, Cavalcanti RB, van Walraven C. Derivation and validation of a novel risk score to predict overcorrection of severe hyponatremia: the Severe Hyponatremia Overcorrection Risk (SHOR) score. Clin J Am Soc Nephrol. (2019) 14:975–82. 10.2215/CJN.12251018
    1. George JC, Zafar W, Bucaloiu ID, Chang AR. Risk factors and outcomes of rapid correction of severe hyponatremia. Clin J Am Soc Nephrol. (2018) 13:984–92. 10.2215/CJN.13061117
    1. Rondon-Berrios H. Therapeutic relowering of plasma sodium after overly rapid correction of hyponatremia: what is the evidence? Clin J Am Soc Nephrol. (2020) 15:282–4.
    1. Krisanapan P, Vongsanim S, Pin-On P, Ruengorn C, Noppakun K. Efficacy of furosemide, oral sodium chloride, and fluid restriction for treatment of Syndrome of Inappropriate Antidiuresis (SIAD): an open-label randomized controlled study (The EFFUSE-FLUID Trial). Am J Kidney Dis. (2020) 76:203–12. 10.1053/j.ajkd.2019.11.012
    1. Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Arici B, Bally M, et al. . Symptoms and characteristics of individuals with profound hyponatremia: a prospective multicenter observational study. J Am Geriatrics Soc. (2015) 63:470–5. 10.1111/jgs.13325
    1. Winzeler B, Jeanloz N, Nigro N, Suter-Widmer I, Schuetz P, Arici B, et al. . Long-term outcome of profound hyponatremia: a prospective 12 months follow-up study. Eur J Endocrinol. (2016) 175:499–507. 10.1530/EJE-16-0500
    1. McCarthy K, Conway R, Byrne D, Cournane S, O'Riordan D, Silke B. Hyponatraemia during an emergency medical admission as a marker of illness severity & case complexity. Eur J Int Med. (2019) 59:60–4. 10.1016/j.ejim.2018.08.002
    1. Kutz A, Ebrahimi F, Aghlmandi S, Wagner U, Bromley M, Illigens B, et al. . Risk of Adverse clinical outcomes in hyponatremic adult patients hospitalized for acute medical conditions: a population-based cohort study. J Clin Endocrinol Metabol. (2020) 105:3428–36. 10.1210/clinem/dgaa547
    1. Cuesta M, Garrahy A, Slattery D, Gupta S, Hannon AM, McGurren K, et al. . Mortality rates are lower in SIAD, than in hypervolaemic or hypovolaemic hyponatraemia: results of a prospective observational study. Clin Endocrinol. (2017) 87:400–6. 10.1111/cen.13388
    1. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia? Clin J Am Soc Nephrol. (2011) 6:960–5.
    1. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. J Assoc Physicians. (2006) 99:505–11. 10.1093/qjmed/hcl071
    1. Sterns RH. Treatment of severe hyponatremia. Clinical Journal of the American Society of Nephrology. (2018) 13:641–9.
    1. Garrahy A, Cuesta M, Murphy B, Tormey W, O'Reilly MW, Sherlock M, et al. . Active management of severe hyponatraemia is associated with improved mortality. Eur J Endocrinol. (2020) 184:9–17.
    1. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA. (1999) 281:2299–304.
    1. Ayus JC, Arieff AI. Pulmonary complications of hyponatremic encephalopathy: noncardiogenic pulmonary edema and hypercapnic respiratory failure. Chest. (1995) 107:517–21.
    1. Ayus JC, Armstrong D, Arieff AI. Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents. Kidney Int. (2006) 69:1319–25. 10.1038/sj.ki.5000187
    1. Vexler ZS, Ayus JC, Roberts TP, Fraser CL, Kucharczyk J, Arieff AI. Hypoxic and ischemic hypoxia exacerbate brain injury associated with metabolic encephalopathy in laboratory animals. J Clin Invest. (1994) 93:256–64. 10.1172/JCI116953
    1. Portales-Castillo I, Sterns RH. Allostasis and the clinical manifestations of mild to moderate chronic hyponatremia: no good adaptation goes unpunished. Am J Kidney Dis. (2019) 73:391–9. 10.1053/j.ajkd.2018.10.004
    1. Jackson PS, Strange K. Volume-sensitive anion channels mediate swelling-activated inositol and taurine efflux. Am J Physiol Cell Physiol. (1993) 265:C1489–500. 10.1152/ajpcell.1993.265.6.C1489
    1. Vandenberg JI, Rees SA, Wright AR, Powell T. Cell swelling and ion transport pathways in cardiac myocytes. Cardiovascular Res. (1996) 32:85–97. 10.1016/S0008-6363(96)00048-X
    1. Schaffer SW, Jong CJ, Ramila KC, Azuma J. Physiological roles of taurine in heart and muscle. J Biomed Sci. (2010) 17:1–8. 10.1186/1423-0127-17-S1-S2
    1. Pion PD, Kittleson MD, Rogers QR, Morris JG. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science. (1987) 237:764–8. 10.1126/science.3616607
    1. Moise NS, Pacioretty LM, Kallfelz FA, Stipanuk MH, King JM, Gilmour RF, Jr. Dietary taurine deficiency and dilated cardiomyopathy in the fox. Am Heart J. (1991) 121:541–7. 10.1016/0002-8703(91)90724-V
    1. Barsony J, Manigrasso MB, Xu Q, Tam H, Verbalis JG. Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats. Age. (2013) 35:271–88. 10.1007/s11357-011-9347-9
    1. Fucà G, Mariani L, Vullo SL, Galli G, Berardi R, Di Nicola M, et al. . Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. Sci Rep. (2019) 9:12993. 10.1038/s41598-019-49601-3
    1. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth Factors. (2010) 28:394–408. 10.3109/08977194.2010.518616
    1. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem. (2001) 276:16649–54. 10.1074/jbc.M010842200
    1. Donner A, Klar N. Pitfalls of and controversies in cluster randomization trials. Am J Public Health. (2004) 94:416–22. 10.2105/AJPH.94.3.416

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir